1. 106176585 一种奥硝唑注射液的制备方法
CN
07.12.2016
A61K 9/08 Loading...
A61K 9/08
Loading...
102016000541668
山西普德药业有限公司
王勇
A61K 9/08
Loading...
本申请公开了一种奥硝唑注射液的制备方法，包括如下步骤：在配料罐中依次加入处方量丙二醇、奥硝唑和乙醇，边加热边搅拌，得到混合溶液，将所述混合溶液调节pH值至4.0～4.5；在所得的混合溶液中加入活性炭，边加热边搅拌吸附，吸附完全后，趁热经微孔滤膜过滤脱炭得到滤液；取滤液搅拌后取样检验；检验合格后将所述滤液经过精滤后装入安瓿中，在110‑118℃条件下灭菌20‑25分钟，之后再在118‑125℃条件下灭菌5‑8分钟，即得所述的奥硝唑注射液。此制备方法简单可靠，且所制备出的奥硝唑注射液稳定性好，有关物质含量低。
2. 105997861 一种人参多糖注射液及其制备方法
CN
12.10.2016
A61K 9/08 Loading...
A61K 9/08
Loading...
102016000541656
山西普德药业有限公司
王勇
A61K 9/08
Loading...
本申请公开了一种人参多糖注射液，所述注射液包括如下组分：人参多糖5‑8重量份；亚硫酸氢钠1‑3重量份；聚山梨酯‑800.5‑2重量份；注射用水适量；其中人参多糖以以半乳糖醛酸纯品计。该注射液稳定性高，有关物质的含量低。根据本申请的另一方面，还提供了一种人参多糖注射液的制备方法，其制备工艺简单可行，避免了活性炭在高温吸附的过程中吸附的主药人参多糖而造成原料的大大的浪费，节约了成本。
3. 105708792 一种还原型羧烷基葡聚糖铁注射液及其制备方法
CN
29.06.2016
A61K 9/08 Loading...
A61K 9/08
Loading...
201610067777.9
山西普德药业股份有限公司
李立忠
A61K 9/08
Loading...
本申请提供了一种还原型羧烷基葡聚糖铁注射液，其包括作为活性成分的还原型羧烷基葡聚糖铁，任选的酸碱调节剂和注射用水。本申请还提供了一种还原型羧烷基葡聚糖铁注射液的制备方法。本申请所提供的注射液具有比现有技术获得的铁注射液更低的可见异物检出率，具有良好的性能如物理稳定性好和/或化学稳定性好。
4. 105708805 一种还原型羧烷基葡聚糖铁及其制备方法
CN
29.06.2016
A61K 9/14 Loading...
A61K 9/14
Loading...
201610067790.4
山西普德药业股份有限公司
李立忠
A61K 9/14
Loading...
本申请公开了一种还原型羧烷基葡聚糖铁及其制备方法，该还原型羧烷基葡聚糖铁为纳米颗粒，具有安全性高、诱发过敏等反应几率低的特点，能够有效降低高浓度的铁离子对人体的副反应，可以大幅减少静脉注射的时间，生物活性高、效果好、副反应少、同时大大减少给药次数。
5. 105622661 一种依折麦布中间体的分子筛催化合成方法
CN
01.06.2016
C07F 7/18 Loading...
C07F 7/18
Loading...
201511016734.X
山西普德药业股份有限公司
王勇
C07F 7/18
Loading...
本申请公开了一种依折麦布中间体3-[(2R,5S)-5-(4-氟苯基)-2-[(S)-[(4-氟苯基(氨基)]][4-R1氧基]苯基]甲基]-1-氧代-5-[(三甲基硅)氧]苯基]-4-苯基-(4S)-2-噁唑烷酮的合成方法，通过采用固体H-ZSM-5分子筛催化剂和/或Co-ZSM-5分子筛催化剂代替了原有的四氯化钛和异丙醇钛催化剂，降低了环境污染和对生产设备的要求，解决了催化剂的分离和回收问题，为依折麦布的大规模连续生产奠定了基础。
6. 105616372 一种还原型羧烷基葡聚糖铁片剂
CN
01.06.2016
A61K 9/26 Loading...
A61K 9/26
Loading...
201610067767.5
山西普德药业股份有限公司
王勇
A61K 9/26
Loading...
本申请公开了一种还原型羧烷基葡聚糖铁片剂组合物，其特征在于，含有还原型羧烷基葡聚糖铁和辅料；所述还原型羧烷基葡聚糖铁由氢氧化铁纳米核体和半合成多糖层构成，所述半合成多糖层包覆在所述氢氧化铁纳米核体外，所述氢氧化铁纳米核体为水溶性胶体粒子；所述辅料包括崩解剂、填充剂、粘合剂和润滑剂。该片剂组合物用于治疗铁缺乏病症，不仅生物活性高、效果好、副反应少，而且安全性高，诱发过敏等反应几率低，有效地降低了高浓度的铁离子对人体的副反应，可以大幅药物服用次数。
7. 105566374 一种依折麦布中间体的浆态床连续生产方法
CN
11.05.2016
C07F 7/18 Loading...
C07F 7/18
Loading...
201511016609.9
山西普德药业股份有限公司
王宝琴
C07F 7/18
Loading...
本申请公开了一种依折麦布中间体3-[(2R,5S)-5-(4-氟苯基)-2-[(S)-[(4-氟苯基(氨基)]][4-R1氧基]苯基]甲基]-1-氧代-5-[(三甲基硅)氧]苯基]-4-苯基-(4S)-2-噁唑烷酮的连续生产方法，其特征在于，将含有化合物A和化合物B的原料，在浆态床反应器中与固体酸催化剂接触反应，制备所述依折麦布中间体。通过采用固体酸催化剂代替了原有的四氯化钛和异丙醇钛催化剂，并在浆态床反应器中连续反应，降低了环境污染和对生产设备的要求，解决了催化剂的分离和回收问题，使依折麦布的大规模连续生产成为可能。
8. 105566375 一种依折麦布中间体的催化合成方法
CN
11.05.2016
C07F 7/18 Loading...
C07F 7/18
Loading...
201511022348.1
山西普德药业股份有限公司
王宝琴
C07F 7/18
Loading...
本申请公开了一种依折麦布中间体3-[(2R,5S)-5-(4-氟苯基)-2-[(S)-[(4-氟苯基(氨基)]][4-R1氧基]苯基]甲基]-1-氧代-5-[(三甲基硅)氧]苯基]-4-苯基-(4S)-2-噁唑烷酮的催化合成方法，通过采用AlCl3/SiO2催化剂或SO42-/TiO2固体酸催化剂代替了原有的四氯化钛和异丙醇钛催化剂，降低了环境污染和对生产设备的要求，解决了催化剂的分离和回收问题，使依折麦布的大规模连续生产成为可能。
9. 105481860 一种他达拉非I型晶体的精制工艺
CN
13.04.2016
C07D 471/14 Loading...
C07D 471/14
Loading...
201511018046.7
山西普德药业股份有限公司
李立忠
C07D 471/14
Loading...
本申请公开了一种他达拉非I型晶体的精制工艺，通过将他达拉非粗品的异丙醇溶液，通入载有固体吸附剂床层的吸附塔，在进行重结晶纯化，可实现他达拉非I型晶体生产工艺中纯化步骤的连续生产，在高产率的得到高纯度他达拉非I型晶体的同时，可实现固体吸附剂的回收和循环利用。
10. 105456207 一种盐酸吉西他滨冻干剂制备方法
CN
06.04.2016
A61K 9/19 Loading...
A61K 9/19
Loading...
201511026304.6
山西普德药业股份有限公司
李立忠
A61K 9/19
Loading...
本申请公开了一种盐酸吉西他滨冻干剂制备方法，步骤如下：a)将盐酸吉西他滨、骨架材料、缓冲剂加水溶解后，用pH调节剂调节溶液pH至2.5～3.5，得到溶液A；b)将步骤a)得到的溶液A与活性炭接触，过滤，收集滤液，冷冻干燥，得到盐酸吉西他滨冻干剂。本方法获得的冻干剂符合标准，操作简单、成本低，适合工业化生产。
11. 105418487 咔唑磺酰胺衍生物共晶及其制备方法
CN
23.03.2016
C07D 209/88 Loading...
C07D 209/88
Loading...
201510708778.2
山西普德药业股份有限公司
李立忠
C07D 209/88
Loading...
本申请公开了一种新型咔唑磺酰胺衍生物共晶及其制备方法。该咔唑磺酰胺衍生物共晶由草酸、马来酸、丙二酸或戊二酸与咔唑磺酰胺衍生物形成，具有抗微管作用，能够显著的抗肿瘤活性，并且具有合成简单、毒副作用小、溶出度和溶解度高的优点。
12. 105418475 一种奥拉西坦的精制工艺
CN
23.03.2016
C07D 207/273 Loading...
C07D 207/273
Loading...
201511022313.8
山西普德药业股份有限公司
李立忠
C07D 207/273
Loading...
本申请公开了一种奥拉西坦的精制工艺，通过将奥拉西坦粗品的甲醇溶液，通入载有固体吸附剂床层的吸附塔，在进行重结晶纯化，可实现奥拉西坦生产工艺中纯化步骤的连续生产，在高产率的得到高纯度奥拉西坦的同时，可实现固体吸附剂的回收和循环利用。
13. 105287388 高分散咔唑磺酰胺衍生物及其制备方法
CN
03.02.2016
A61K 9/14 Loading...
A61K 9/14
Loading...
201510708761.7
山西普德药业股份有限公司
王勇
A61K 9/14
Loading...
本申请公开了一种负载咔唑磺酰胺衍生物的纳米粒，包括无机纳米载体和所述无机纳米载体上吸附的咔唑磺酰胺衍生物。所述纳米粒通过将活性组分咔唑磺酰胺衍生物负载在无机纳米材料上，大幅提高了活性组分咔唑磺酰胺衍生物的溶出度和溶解度。
14. 103319390 一种前列地尔化合物及其组合物
CN
25.09.2013
C07C 405/00 Loading...
C07C 405/00
Loading...
201310286747.3
山西普德药业股份有限公司
王勇
C07C 405/00
Loading...
本发明公开了一种前列地尔化合物及其组合物，具体通过提供一种全新的前列地尔化合物来提高作为制剂原料的前列地尔本身及其组合物制剂的稳定性。该化合物与市售的前列地尔粗品在相同的检测条件下得到的X射线粉末衍射图显示完全不同的特征峰。本发明提供的前列地尔制备方法简单，生产成本低，是一种高质量的现有前列地尔原料药的替代品。
15. 103193604 一种细辛脑化合物及其冻干粉针剂
CN
10.07.2013
C07C 43/205 Loading...
C07C 43/205
Loading...
201310153928.9
山西普德药业股份有限公司
李立忠
C07C 43/205
Loading...
本发明公开了一种全新活性的细辛脑化合物，该细辛脑化合物本身及其制剂在稳定性试验等均表现出显著优于现有细辛脑化合物的优势。由于细辛脑化合物能够显著改善制剂的稳定性，从而能够保障患者的用药安全。此外，本发明进一步公开了上述细辛脑化合物的制备方法及含有该细辛脑化合物的冻干粉针制剂。
16. 103110656 一种注射用水溶性维生素冻干制剂及其制备方法
CN
22.05.2013
A61K 31/714 Loading...
A61K 31/714
Loading...
201310054552.6
山西普德药业股份有限公司
王勇
A61K 31/714
Loading...
本发明公开了一种注射用水溶性维生素冻干制剂，所述冻干制剂由包含如下组分的原料制备成1000瓶：硝酸硫胺2.8-3.4g；烟酰胺36-44g；盐酸吡哆辛4.4-5.4g；泛酸钠化合物14.8-18.1g；核黄素磷酸钠4.4-5.4g；维生素C钠102-124g；生物素54-66mg；叶酸0.36-0.44g；维生素B124.5-6.0mg；对羟基苯甲酸甲酯0.4-0.6g；甘氨酸280-320g；乙二胺四乙酸二钠0.4-0.6g；注射用水2000-3000ml。本发明所得泛酸钠钠化合物显著提高了现有泛酸钠的稳定性，从而确保含有泛酸钠的注射用水溶性微生物冻干制剂具有理想的稳定性和疗效，进一步保证了患者的用药安全。
17. 103110616 一种注射用门冬氨酸钾镁冻干粉针制剂及其制备方法
CN
22.05.2013
A61K 31/198 Loading...
A61K 31/198
Loading...
201310081059.3
山西普德药业股份有限公司
李立忠
A61K 31/198
Loading...
本发明涉及一种注射用门冬氨酸钾镁冻干粉针制剂，所述制剂按重量份计，由包括以下组分的原料制备而成：门冬氨酸钾400-600份、门冬氨酸镁400-600份和乳糖320-480份。本发明所述的冻干制剂具有处方简单、制备方法科学合理的优点，使得冻干制得的药品更加蓬松多孔，显著提高其在临床使用时的复溶性，同时，在辅料用量低，种类少的前提下还能进一步提高制剂的稳定性，从而确保了患者的用药安全。
18. 103113372 一种高收率的左亚叶酸钙的制备方法
CN
22.05.2013
C07D 475/04 Loading...
C07D 475/04
Loading...
201310080834.3
山西普德药业股份有限公司
王勇
C07D 475/04
Loading...
本发明属于药物合成领域，涉及一种抗肿瘤药物的制备方法，具体涉及一种高收率的左亚叶酸钙的制备方法；其发明特点在于：通过拆分工艺制备左亚叶酸钙，拆分过程中加入了含有左亚叶酸钙的溶液，左亚叶酸钙溶液中左亚叶酸钙占到亚叶酸钙总量的70％以上，该方法既提高了拆分收率，又回收利用了拆分工艺产生的母液，在工业生产中有较大意义。
19. 103040740 一种奥硝唑注射液及制备工艺
CN
17.04.2013
A61K 9/08 Loading...
A61K 9/08
Loading...
201310028025.8
山西普德药业股份有限公司
李立忠
A61K 9/08
Loading...
本发明提供了一种奥硝唑注射液，注射液由奥硝唑、丙二醇和注射用水组成。丙二醇的体积用量是注射液体积的60%～70%时可以使奥硝唑很好溶解；本发明在制备奥硝唑注射液的工艺中，用二氧化碳气体充分将溶液内的氧气排去，注射液中饱和的二氧化碳气体，不仅减少了奥硝唑注射液氧化副产物，也提高了奥硝唑注射液的热稳定性。
20. 103040834 一种注射用培美曲塞二钠及其制备方法
CN
17.04.2013
A61K 31/519 Loading...
A61K 31/519
Loading...
201210569901.3
山西普德药业股份有限公司
李立忠
A61K 31/519
Loading...
本发明公开了一种注射用培美曲塞二钠，所述注射用培美曲塞二钠按重量份计，由包括如下组分的原料制备而成：培美曲塞二钠化合物50-60份、甘露醇20-40份及精氨酸2-4份；此外，本发明还提供了一种培美曲塞二钠化合物，该培美曲塞二钠化合物稳定性得到显著提高，有机溶剂残余量低，质量可控，长时间放置不易发生变化，大大提高了患者用药安全。
21. 103006683 注射用12种复合维生素药物组合物及制备方法
CN
03.04.2013
A61K 31/714 Loading...
A61K 31/714
Loading...
201310011665.8
山西普德药业股份有限公司
李立忠
A61K 31/714
Loading...
本发明提供了注射用12种复合维生素药物组合物及制备方法，本发明的注射用12种复合维生素药物组合物包括活性成分维生素A棕榈酸酯、胆骨化醇、消旋α-生育酚、抗坏血酸、烟酰胺、右泛醇、盐酸吡多辛、核黄素磷酸钠、四水合硫胺焦磷酸酯、叶酸、D-生物素、氰钴胺及辅料聚山梨酯80、甘露醇组成；本发明的处方不含有辅料甘氨胆酸，临床可用于甘氨胆酸过高的人群。
22. 102977107 一种培美曲塞二钠化合物及其组合物
CN
20.03.2013
C07D 487/04 Loading...
C07D 487/04
Loading...
201210569873.5
山西普德药业股份有限公司
王勇
C07D 487/04
Loading...
本发明公开了一种式（I）所示培美曲塞二钠化合物及其组合物，所述培美曲塞二钠化合物用粉末X射线衍射测定法测定，以2θ±0.2衍射角表示的X射线粉末衍射图谱在10.05°、10.90°、11.40°、12.51°、14.22°、15.94°、18.33°、19.72°、21.44°、22.92°、23.84°、28.08°、29.98°、31.95°和33.32°处显示出特征衍射峰；本发明提供的培美曲塞二钠化合物稳定性得到显著提高，有机溶剂残余量低，质量可控，长时间放置不易发生变化，大大提高了患者用药安全。
23. 102973501 氨甲环酸注射液及其制备方法
CN
20.03.2013
A61K 9/08 Loading...
A61K 9/08
Loading...
201210569736.1
山西普德药业股份有限公司
胡成伟
A61K 9/08
Loading...
本发明提供了氨甲环酸注射液及其制备方法，本发明对制备工艺中加入的针用活性炭进行预处理：用丙酮，乙醇、乙二胺四乙酸水溶液对针用活性炭进行洗涤，干燥，以除去针用活性炭中残留的金属及其他杂质，用预处理过的针用活性炭用于制备氨甲环酸注射液，可以减少杂质-Z-异构体的生成，保证了氨甲环酸注射液的质量。
24. 102127068 Method for synthesizing aztreonam compound
CN
20.07.2011
C07D 417/12 Loading...
C07D 417/12
Loading...
201010624073.X
Shanxi Powerdone Pharmaceutics Co., Ltd.
Jie Xiaorong
C07D 417/12
Loading...
The invention relates to a method for synthesizing an aztreonam compound. The method comprises the following steps of: (1) adding water and a water-soluble non-aqueous solvent into a reaction container, adding trans-3(S)-amino-4-methyl-2-keto-1-azetidine sulfonic acid, triethylamine and (Z)-2-[(2-aminothiazole-4-radical)-(benzothiazole-2-sulfenyl carbonyl) methylamine oxygroup]-2-methylpropanoic acid tert-butyl ester for reacting, and adjusting the pH with acid and separating crystals out to obtain tertiary butyl aztreonam; and (2) subjecting the tertiary butyl aztreonam and acid-water mixed liquor to reaction and performing post-treatment to obtain aztreonam. By adopting the method, the reaction time can be shortened, the reaction speed can be increased, the production cost can be lowered, and environmental pollution can be reduced.
25. 102068411 Carbazole sulfonamide type anti-tumor medicament granules and preparation method thereof
CN
25.05.2011
A61K 9/16 Loading...
A61K 9/16
Loading...
201010608606.5
Shanxi Powerdone Pharmaceutics Co., Ltd.
Li Lizhong
A61K 9/16
Loading...
The invention belongs to the field of medicament preparations and relates to a preparation method of an anti-tumor preparation, in particular to carbazole sulfonamide type anti-tumor medicament granules and the preparation method thereof, and the preparation method is characterized in that lactose and beta-cyclodextrin are added in a carbazole sulfonamide type medicament which is N-(2,6-dimethoxy pyridine-3-substituted)-9-methylcarbazole-3-sulfonamide, the mixing is performed, the mixture is milled to micro-powder and prepared into granules, and the dissolution rate of the granules can be improved.
26. 102068415 Carbazole sulfonamide anti-tumor medicine dispersible tablets and preparation method thereof
CN
25.05.2011
A61K 9/20 Loading...
A61K 9/20
Loading...
201010608590.8
Shanxi Powerdone Pharmaceutics Co., Ltd.
Li Lizhong
A61K 9/20
Loading...
The invention belongs to the field of pharmaceutic preparation and relates to a method for preparing anti-tumor preparations, in particular to carbazole sulfamide-derived anti-tumor medicine dispersible tablets and a preparation method thereof. The invention is characterized in that lactose and beta-cyclodextrin are mixed with a carbazole sulfamide-derived medicine such as N-(2, 6-dimethoxypyridine-3-substituted)-9-methyl carbazole-3-sulfamide, for mixing, and the mixture is ground to micro powder and prepared into the dispersible tablets. Therefore, the dissolution rate of the dispersible tablets can be increased.
27. 102068431 Carbazole sulfamide-derived anti-tumor medicine tablets and preparation method thereof
CN
25.05.2011
A61K 31/4439 Loading...
A61K 31/4439
Loading...
201010608557.5
Shanxi Powerdone Pharmaceutics Co., Ltd.
Jie Xiaorong
A61K 31/4439
Loading...
The invention belongs to the field of pharmaceutic preparation and relates to a method for preparing anti-tumor preparations, in particular to carbazole sulfamide-derived anti-tumor medicine tablets and a preparation method thereof. The invention is characterized in that lactose and beta-cyclodextrin are added to a carbazole sulfamide-derived medicine, i.e. N-(2,6-dimethoxypyridine-3-substitution)-9-methyl carbazole-3-sulfamide, for mixing, and the mixture is ground to micro powder and prepared into the tablets. Therefore, the dissolution rate of the tablets can be increased.
28. 102038663 Carbazole sulfonamide antineoplastic agent capsules and preparation method
CN
04.05.2011
A61K 9/48 Loading...
A61K 9/48
Loading...
201010608593.1
Shanxi Powerdone Pharmaceutics Co., Ltd.
Xie Xiaorong
A61K 9/48
Loading...
The invention belongs to the field of pharmaceutic preparations and relates to a preparation method of the antineoplastic agent, in particular to carbazole sulfonamide antineoplastic agent capsules and a preparation method thereof. The carbazole sulfonamide antineoplastic agent capsules are characterized in that: lactose and beta-cyclodextrin are added into a carbazole sulfonamide medicine, namely N-(2,6-dimethypyridine-3-yl)-9-methylcarbazole-3-sulfamide; the materials are mixed and ground into micro powder; the micro powder is granulated, and the granulates are formed into capsules; and the dissolution rate of the capsules are improved.
29. 101962379 Method for refining sulfonyl isoquinoline derivative
CN
02.02.2011
C07D 401/12 Loading...
C07D 401/12
Loading...
201010502306.9
Shanxi Powerdone Pharmaceutics Co., Ltd.
Hu Chengwei
C07D 401/12
Loading...
The invention relates to a method for refining a sulfonyl isoquinoline derivative generally known as a Fasudil hydrochloride medicament for treating cerebral spasm caused by subarachnoid hemorrhage. The method of the invention comprises the steps of purification and refining and salification, wherein the step of purification comprises washing with water, concentrating, acidifying, extracting and crystallizing; and the step of salification and refining combines the Fasudil salification and subsequent refining of the prior art. The purification, refining and salification method of the invention has the advantages of simplifying operation flow, shortening production period, reducing production cost, improving product quality and bringing a great convenience to industrial production.
30. 101953807 Mycophenolate mofetil lyophilized powder injection for injection and preparation method thereof
CN
26.01.2011
A61K 9/19 Loading...
A61K 9/19
Loading...
201010505035.2
Shanxi Pude Pharmaceutical Co., Ltd.
Hu Chengwei
A61K 9/19
Loading...
The invention provides a mycophenolate mofetil lyophilized powder injection for injection. The injection is prepared from mycophenolate mofetil serving as an active ingredient and polyethylene glycol-12-hydroxy stearate serving as a solubilizing agent in a weight ratio of 250-1,250:100-500. The invention also provides a method for preparing the mycophenolate mofetil lyophilized powder injection for injection. The mycophenolate mofetil lyophilized powder injection for injection has the advantages of simple and reasonable prescription, stable quality, convenient use, capabilities of preventing adverse reactions such as nausea, vomit, diarrhea and the like caused by oral preparations and the like and preventing toxic or side effects such as drop of blood pressure, hemolysis and the like caused by solubilizing agents such as Twain 80 and the like, high safety and good application prospect.
31. 101947247 Method for preparing ginkgodipyidamolum injection
CN
19.01.2011
A61K 36/16 Loading...
A61K 36/16
Loading...
201010502318.1
Shanxi Powerdone Pharmaceutics Co., Ltd.
Hu Chengwei
A61K 36/16
Loading...
The invention provides a method for preparing ginkgodipyidamolum injection. The method comprises the following steps of: 1) extracting a ginkgo leaf extract from ginkgo leaves; 2) extracting the ginkgo leaf extract once again with over 90 percent ethanol so as to refine the ginkgo leaf extract; 3) adding water into the refined ginkgo leaf extract and dipyridamole for inverse flow and filtering so as to obtain ginkgo leaf extracting solution; and 4) mixing the ginkgo leaf extracting solution, the dipyridamole and auxiliary materials so as to obtain the ginkgodipyidamolum injection, wherein in the ginkgodipyidamolum injection, the weight ratio of the ginkgo leaf extracting solution to the dipyridamole based on total ginkgo flavone-glycoides is 0.9-1.1:0.3-0.5. The method of the invention has the advantages of effectively removing various impurities, enhancing medicament effectiveness, improving the quality stability of the ginkgodipyidamolum injection and reducing safety risk.
32. 101444492 Lomefloxacin hydrochloride lyophilized powder for injection and preparation method therefor
CN
03.06.2009
A61K 9/19 Loading...
A61K 9/19
Loading...
200810239013.9
Shanxi Pude Pharmaceutical Co., Ltd.
Hu Chengwei
A61K 9/19
Loading...
The invention relates to a lomefloxacin hydrochloride lyophilized powder for injection and a preparation method therefor. The lomefloxacin hydrochloride lyophilized powder for injection is prepared by an active ingredient of lomefloxacin hydrochloride, an acceptable lyophilized powder for injection excipient on pharmacy and a buffer solution with the pH value being 3.0-6.5, and the proportion of the three components is (50-150): (20-60): (1500-3500) (g:g:ml). The lomefloxacin hydrochloride lyophilized powder for injection has the advantages that the efficacy of the lyophilized powder for injection is stable, the lyophilized powder for injection is not easily decomposed and separated, the application is convenient, the tolerance is good, the physiological stimulation is slight, and the lyophilized powder for injection can be stably deposited for a long term.

